
  
    
      
        Background_NNP
        Schizophrenia_NNP and_CC associated_VBN mental_JJ illness_NN are_VBP complex_JJ
        psychiatric_JJ disorders_NNS each_DT affecting_VBG about_IN 1_CD %_NN of_IN the_DT world_NN
        population_NN ._. Genetic_JJ evaluation_NN of_IN Schizophrenia_NNP and_CC
        associated_VBN mental_JJ illness_NN have_VBP suggested_VBN an_DT important_JJ role_NN
        for_IN genetic_JJ factors_NNS [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ,_, however_RB ,_, no_DT specific_JJ gene_NN
        or_CC biological_JJ marker_NN has_VBZ yet_RB been_VBN identified_VBN ._. Genome_NNP scans_NNS
        have_VBP mapped_VBN several_JJ loci_NN in_IN various_JJ ethnic_JJ groups_NNS ._.
        Replications_NNP of_IN these_DT scans_NNS were_VBD positive_JJ in_IN some_DT cases_NNS and_CC
        negative_JJ in_IN others_NNS [_NN 2_CD 5_CD 6_CD ]_NN ._. These_DT data_NNS as_RB well_RB as_IN
        reports_NNS of_IN the_DT specific_JJ candidate_NN genes_NNS beginning_VBG to_TO be_VB
        identified_VBN implicate_VB genetic_JJ heterogeneity_NN of_IN
        susceptibility_NN genes_NNS [_NN 7_CD 8_CD ]_NN and_CC also_RB sex_NN specific_JJ
        differences_NNS [_NN 9_CD ]_NN in_IN the_DT molecular_JJ basis_NN of_IN disease_NN
        phenotype_NN ._. Linkage_NNP analyses_NNS of_IN all_DT published_VBN genome_NN scans_VBZ ,_,
        for_IN Schizophrenia_NNP genes_NNS ,_, have_VBP identified_VBN chromosome_NN 13_CD q_NN 32_CD
        as_IN one_CD of_IN the_DT regions_NNS with_IN evidence_NN of_IN linkage_NN to_TO
        Schizophrenia_NNP ._. In_IN independent_JJ genome_NN scans_VBZ ,_, Bipolar_NNP
        disorder_NN has_VBZ also_RB shown_VBN linkage_NN to_TO this_DT region_NN [_NN 10_CD 11_CD 12_CD
        13_CD ]_NN ._. The_DT linkage_NN region_NN for_IN both_DT disorders_NNS spans_NNS
        approximately_RB 10_CD cM_NN on_IN chromosome_NN 13_CD q_NN 32_CD -_: q_NN 33_CD [_NN 14_CD ]_NN ._. The_DT
        region_NN between_IN D_NNP 13_CD S_NNP 71_CD and_CC D_NNP 13_CD S_NNP 274_CD showed_VBD linkage_NN to_TO
        Bipolar_NNP disorder_NN based_VBN on_IN a_DT whole_JJ genome_NN scan_VB with_IN an_DT
        average_JJ marker_NN spacing_VBG of_IN ~_NN 6_CD cM_NN on_IN 13_CD q_NN 32_CD ._. Fine_JJ mapping_NN of_IN
        this_DT region_NN ,_, using_VBG nine_CD additional_JJ markers_NNS ,_, with_IN an_DT average_JJ
        spacing_VBG of_IN 0_CD ._. 9_CD cM_NN confirms_VBZ the_DT evidence_NN of_IN linkage_NN to_TO 13_CD q_NN 32_CD
        around_IN markers_NNS D_NNP 13_CD S_NNP 79_CD -_: D_NNP 13_CD S_NNP 225_CD [_NN 15_CD ]_NN ._. Association_NNP analyses_NNS
        with_IN GASSOC_NNP TDT_NNP and_CC ASPEX_NNP /_NN Sib_NNP __NN tdt_NN showed_VBD linkage_NN
        disequilibrium_NN signals_NNS with_IN several_JJ markers_NNS ,_, including_VBG
        D_NNP 13_CD S_NNP 280_CD which_WDT need_VBP follow_VB up_RB by_IN typing_VBG more_JJR markers_NNS in_IN the_DT
        region_NN in_IN a_DT larger_JJR sample_NN size_NN [_NN 15_CD ]_NN ._. Meta_NNP analysis_NN of_IN
        whole-genome_JJ linkage_NN scans_VBZ further_JJ strengthens_VBZ the_DT
        susceptibility_NN locus_JJ of_IN BP_NNP on_IN chromosome_NN 13_CD q_NN 32_CD [_NN 13_CD ]_NN ._. All_DT
        these_DT studies_NNS clearly_RB point_VBP towards_IN further_JJ efforts_NNS in_IN the_DT
        identification_NN of_IN susceptibility_NN genes_NNS for_IN this_DT disorder_NN ._.
        Based_VBN on_IN evidence_NN of_IN linkage_NN ,_, a_DT comprehensive_JJ linkage_NN map_NN
        was_VBD developed_VBN around_IN this_DT region_NN [_NN 14_CD ]_NN ._. Complete_JJ
        annotation_NN of_IN this_DT region_NN may_MD include_VB as_RB many_JJ as_IN 200_CD genes_NNS ._.
        One_CD approach_NN to_TO identify_VB susceptibility_NN locus_JJ is_VBZ to_TO use_VB the_DT
        candidate_NN gene_NN approach_NN ._. Studies_NNS are_VBP underway_NN at_IN our_PRP$ center_NN
        to_TO identify_VB susceptibility_NN variants_NNS by_IN mutation_NN screening_NN
        of_IN candidate_NN genes_NNS in_IN this_DT region_NN on_IN a_DT small_JJ series_NN of_IN
        Bipolar_NNP families_NNS showing_VBG linkage_NN to_TO 13_CD q_NN 32_CD ._. For_IN the_DT present_JJ
        study_NN we_PRP have_VBP selected_VBN two_CD candidate_NN genes_NNS viz_NN ._. human_JJ
        peptide_NN transporter_NN (_( SLC_NNP 15_CD A_DT 1_LS )_) and_CC human_JJ glypican_NN 5_CD (_( GPC_NNP 5_LS )_)
        for_IN mutation_NN screening_NN from_IN this_DT region_NN ._.
        SLC_NNP 15_CD A_DT 1_CD is_VBZ an_DT intestinal_NN oligopeptide_NN transporter_NN also_RB
        referred_VBD to_TO as_IN HPEPT_NNP 1_CD that_WDT belongs_VBZ to_TO solute_NN carrier_NN
        family_NN 15_CD ._. It_PRP is_VBZ expressed_VBN in_IN intestine_NN ,_, kidney_NN ,_, liver_NN and_CC
        brain_NN [_NN 16_CD ]_NN ._. The_DT function_NN of_IN SLC_NNP 15_CD A_DT 1_CD is_VBZ to_TO absorb_VB and_CC
        transport_VB small_JJ peptides_NNS [_NN 17_CD 18_CD ]_NN ._. The_DT efficiency_NN of_IN
        absorption_NN and_CC transportation_NN of_IN L_NNP DOPA_NNP and_CC its_PRP$ metabolite_NN
        dopamine_NN ,_, which_WDT are_VBP neurotransmitter_NN candidates_NNS ,_, is_VBZ
        increased_VBN by_IN SLC_NNP 15_CD A_DT 1_CD [_NN 19_CD ]_NN ._. Therefore_RB ,_, it_PRP is_VBZ an_DT important_JJ
        potential_JJ gene_NN for_IN future_JJ drug_NN design_NN ,_, delivery_NN ,_, and_CC
        targeting_VBG [_NN 20_CD ]_NN ._.
        GPC_NNP 5_CD belongs_VBZ to_TO the_DT cell_NN surface_NN heparan_NN sulfate_NN
        proteoglycan_NN family_NN and_CC is_VBZ expressed_VBN in_IN limb_NN ,_, kidney_NN ,_,
        developing_VBG central_JJ nervous_JJ system_NN and_CC brain_NN tissue_NN [_NN 21_CD 22_CD
        ]_NN ._. In_IN vertebrates_NNS 6_CD glypican_NN family_NN members_NNS belonging_VBG to_TO
        the_DT proteoglycan_NN family_NN have_VBP so_RB far_RB been_VBN characterized_VBN [_NN 23_CD
        ]_NN ._. Although_IN there_EX is_VBZ a_DT high_JJ degree_NN of_IN conservation_NN of_IN
        polypeptide_NN sequence_NN among_IN family_NN members_NNS ,_, they_PRP are_VBP
        localized_VBN to_TO different_JJ chromosomes_NNS ._. Glypican_NNP 5_CD is_VBZ
        structurally_RB correlated_JJ to_TO glypican_NN 3_CD and_CC localized_VBN to_TO
        chromosome_NN 13_CD q_NN 32_CD ._. Deletion_NNP of_IN the_DT 13_CD q_NN region_NN is_VBZ associated_VBN
        with_IN human_JJ 13_CD q_NN syndrome_NN ,_, a_DT developmental_NN disorder_NN [_NN 24_CD ]_NN ._.
        Some_DT of_IN the_DT proteoglycans_NNS play_VBP important_JJ functional_JJ roles_NNS
        in_IN neurogenesis_NNS ,_, axon_NN guidance_NN ,_, synapse_NN development_NN [_NN 25_CD ]_NN
        ,_, and_CC cellular_JJ growth_NN and_CC differentiation_NN [_NN 26_CD 27_CD 23_CD ]_NN ._.
        Mutations_NNP in_IN GPC_NNP 3_CD cause_VB Simpson-_NNP Golabi-_NNP Behmel_NNP syndrome_NN [_NN 28_CD
        29_CD ]_NN ,_, however_RB ,_, no_DT mutations_NNS were_VBD detected_VBN in_IN the_DT GPC_NNP 5_CD and_CC
        GPC_NNP 6_CD genes_NNS [_NN 30_CD ]_NN ._. The_DT glypican_NN 1_CD gene_NN has_VBZ been_VBN suggested_VBN
        to_TO be_VB a_DT good_JJ candidate_NN for_IN brachydactyly_RB type_NN E_NNP [_NN 31_CD ]_NN ._.
        Given_VBN that_IN ,_, GPC_NNP 5_CD is_VBZ highly_RB expressed_VBN in_IN brain_NN and_CC mutations_NNS
        in_IN other_JJ genes_NNS of_IN the_DT glypican_NN families_NNS are_VBP associated_VBN with_IN
        developmental_NN disorder_NN ;_: GPC_NNP 5_CD could_MD be_VB a_DT potential_JJ candidate_NN
        gene_NN for_IN Bipolar_NNP disorder_NN ._.
        In_IN order_NN to_TO identify_VB a_DT possible_JJ role_NN for_IN these_DT
        candidates_NNS (_( SLC_NNP 15_CD A_DT 1_CD &_CC GPC_NNP 5_LS )_) as_IN susceptibility_NN genes_NNS ,_, we_PRP
        performed_VBD mutation_NN screening_NN of_IN the_DT coding_VBG regions_NNS in_IN 7_CD
        families_NNS (_( n_NN =_SYM 20_CD )_) affected_VBN with_IN Bipolar_NNP disorder_NN showing_VBG
        linkage_NN to_TO 13_CD q_NN 32_CD ._. First_LS ,_, the_DT accurate_JJ gene_NN structure_NN of_IN
        SLC_NNP 15_CD A_DT 1_CD &_CC GPC_NNP 5_CD was_VBD defined_VBN by_IN analysis_NN of_IN the_DT available_JJ
        draft_NN human_JJ genomic_JJ sequence_NN ._. Next_JJ ,_, PCR_NNP primers_NNS and_CC
        conditions_NNS for_IN amplification_NN and_CC sequencing_VBG of_IN each_DT exon_NN
        were_VBD developed_VBN and_CC sequencing_VBG was_VBD performed_VBN ._.
      
      
        Results_NNS
        
          Genomic_NNP structure_NN
          We_PRP determined_VBD genomic_JJ structure_NN of_IN both_DT the_DT genes_NNS by_IN
          aligning_VBG cDNA_NN sequences_NNS with_IN available_JJ human_JJ draft_NN
          genomic_JJ sequences_NNS http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN ._. The_DT
          entire_JJ SLC_NNP 15_CD A_DT 1_CD gene_NN was_VBD represented_VBN in_IN one_CD BAC_NNP clone_NN
          sequence_NN AL_NNP 357553_CD and_CC GPC_NNP 5_CD in_IN 6_CD BAC_NNP clone_NN sequences_NNS ._.
          Alignment_NNP of_IN SLC_NNP 15_CD A_DT 1_CD cDNA_NN sequence_NN (_( accession_NN number_NN
          U_NNP 21936_CD )_) with_IN the_DT genomic_JJ sequence_NN (_( accession_NN no_UH ._.
          AL_NNP 357553_CD )_) revealed_VBD that_IN it_PRP is_VBZ a_DT large_JJ gene_NN with_IN a_DT coding_VBG
          sequence_NN of_IN 3105_CD bp_NN long_JJ ,_, having_VBG 23_CD exons_NNS spread_VBP over_IN
          ~_NN 68_CD ._. 85_CD kb_NN of_IN genomic_JJ sequence_NN ._. The_DT splice_NN junctions_NNS
          follow_VBP the_DT GT_NNP /_NN AG_NNP rule_NN (_( Table_NNP 1_LS )_) ._.
          Alignment_NNP of_IN GPC_NNP 5_CD cDNA_NN (_( accession_NN number_NN U_NNP 66033_CD )_) with_IN
          the_DT working_VBG draft_NN sequence_NN revealed_VBD a_DT genomic_JJ
          organization_NN of_IN 8_CD exons_NNS ,_, which_WDT was_VBD represented_VBN in_IN 6_CD BAC_NNP
          clone_NN sequences_NNS ._. The_DT coding_VBG sequence_NN of_IN GPC_NNP 5_CD gene_NN is_VBZ 2558_CD
          bp_NN long_JJ and_CC encodes_NNS 572_CD amino_JJ acids_NNS ._. The_DT first_JJ two_CD exons_NNS
          of_IN the_DT GPC_NNP 5_CD gene_NN are_VBP present_JJ in_IN BAC_NNP clone_NN accession_NN
          number_NN AL_NNP 138714_CD ,_, exons_NNS 3_CD ,_, 4_CD ,_, 5_CD in_IN AC_NNP 027429_CD ,_, exon_NN 6_CD in_IN
          AL_NNP 162456_CD ,_, exon_NN 7_CD in_IN AL_NNP 163537_CD and_CC exon_NN 8_CD in_IN AL_NNP 157363_CD
          (_( Table_NNP 2_LS )_) ._. Most_JJS of_IN the_DT splice_NN junctions_NNS follow_VBP the_DT GT_NNP /_NN AG_NNP
          rule_NN ._.
        
        
          Mutation_NNP analysis_NN
          No_DT mutations_NNS were_VBD identified_VBN in_IN the_DT GPC_NNP 5_CD gene_NN in_IN the_DT 7_CD
          families_NNS affected_VBN with_IN Bipolar_NNP disorder_NN ._. Two_CD polymorphic_JJ
          variants_NNS were_VBD discovered_VBN in_IN SLC_NNP 15_CD A_DT 1_CD gene_NN ,_, one_CD in_IN exon_NN 17_CD
          and_CC another_DT one_CD in_IN exon_NN 23_CD ._. Sequence_NNP analysis_NN revealed_VBD a_DT
          T_NN to_TO C_NNP (_( Figure_NN 1_CD A_DT )_) substitution_NN in_IN third_JJ position_NN of_IN
          codon_NN encoding_VBG alanine_NN at_IN 1403_CD position_NN of_IN mRNA_NN and_CC A_DT to_TO
          G_NNP (_( Figure_NN 1_CD B_NNP )_) substitution_NN at_IN position_NN 2242_CD of_IN mRNA_NN ._. Of_IN
          these_DT ,_, 6_CD individuals_NNS (_( 3_CD affected_VBN and_CC 3_CD normal_JJ )_) were_VBD
          homozygous_JJ CC_NNP (_( exon_NN 17_CD )_) ,_, 15_CD (_( 11_CD affected_VBN and_CC 4_CD normal_JJ )_)
          were_VBD heterozygous_JJ TC_NNP (_( exon_NN 17_CD )_) and_CC three_CD were_VBD
          heterozygous_JJ AG_NNP (_( exon_NN 23_CD )_) ._.
        
      
      
        Discussion_NNP
        Gene_NNP mapping_NN studies_NNS using_VBG microsatellite_NN markers_NNS have_VBP
        identified_VBN chromosome_NN 13_CD q_NN 32_CD as_IN one_CD of_IN the_DT putative_JJ loci_NN for_IN
        Schizophrenia_NNP and_CC Bipolar_NNP disorder_NN [_NN 10_CD 11_CD 12_CD 13_CD 15_CD ]_NN ._. To_TO
        begin_VB identification_NN of_IN a_DT susceptibility_NN gene_NN for_IN Bipolar_NNP
        disorder_NN ,_, we_PRP have_VBP screened_VBD two_CD candidate_NN genes_NNS ,_, SLC_NNP 15_CD A_DT 1_CD and_CC
        GPC_NNP 5_CD ,_, on_IN the_DT basis_NN of_IN their_PRP$ genetic_JJ localization_NN within_IN the_DT
        10_CD cM_NN region_NN of_IN chromosome_NN 13_CD q_NN 32_CD [_NN 14_CD ]_NN ._. The_DT entire_JJ
        SLC_NNP 15_CD A_DT 1_CD gene_NN was_VBD represented_VBN in_IN one_CD BAC_NNP clone_NN sequence_NN
        AL_NNP 357553_CD and_CC GPC_NNP 5_CD in_IN 6_CD BAC_NNP clone_NN sequences_NNS ._. Alignment_NNP of_IN
        SLC_NNP 15_CD A_DT 1_CD cDNA_NN sequence_NN with_IN genomic_JJ sequence_NN (_( accession_NN no_UH ._.
        AL_NNP 357553_CD )_) revealed_VBD that_IN it_PRP is_VBZ a_DT large_JJ gene_NN with_IN a_DT coding_VBG
        sequence_NN of_IN 3105_CD bp_NN long_JJ ,_, having_VBG 23_CD exons_NNS spread_VBP over_IN
        ~_NN 68_CD ._. 85_CD kb_NN of_IN genomic_JJ sequence_NN ._. The_DT splice_NN junctions_NNS follow_VBP
        the_DT GT_NNP /_NN AG_NNP rule_NN (_( Table_NNP 1_LS )_) ._. A_DT wide_JJ variety_NN of_IN transporters_NNS
        are_VBP found_VBN in_IN the_DT intestine_NN and_CC several_JJ genetic_JJ disorders_NNS
        have_VBP been_VBN shown_VBN to_TO result_VB from_IN deficient_NN intestinal_NN
        transporters_NNS [_NN 20_CD ]_NN ._. SLC_NNP 15_CD A_DT 1_CD consists_VBZ of_IN 708_CD amino_JJ acids_NNS
        with_IN putative_JJ 12_CD transmembrane_NN domains_NNS and_CC 2_CD putative_JJ
        protein_NN kinase_NN C_NNP phosphorylation_NN sites_NNS ._. Exon-intron_NNP
        boundaries_NNS occur_VBP mostly_RB in_IN the_DT loops_NNS connecting_VBG
        transmembrane_NN segments_NNS [_NN 32_CD ]_NN suggesting_VBG a_DT modular_JJ gene_NN
        structure_NN reflecting_VBG the_DT TMS-loop_NNP repeat_NN units_NNS in_IN SLC_NNP 15_CD A_DT 1_CD ._.
        Computer_NN modeling_NN and_CC site_NN directed_VBD mutagenesis_NNS studies_NNS
        suggested_VBD a_DT list_NN of_IN amino_JJ acids_NNS for_IN the_DT transport_NN
        functional_JJ activities_NNS ._. Tyrosine_NNP (_( Y_NNP 167_CD )_) and_CC histidyl_NN
        residues_NNS (_( H_NNP 57_CD ,_, H_NNP 111_CD and_CC H_NNP 121_CD )_) are_VBP two_CD of_IN these_DT amino_JJ acids_NNS
        playing_VBG important_JJ roles_NNS in_IN the_DT function_NN of_IN transporters_NNS [_NN
        33_CD 34_CD 35_CD 36_CD ]_NN ._. In_IN our_PRP$ mutation_NN screening_NN of_IN families_NNS with_IN
        Bipolar_NNP disorder_NN we_PRP did_VBD not_RB find_VB variants_NNS at_IN these_DT
        positions_NNS ._. However_RB ,_, we_PRP did_VBD identify_VB two_CD variants_NNS in_IN the_DT
        SLC_NNP 15_CD A_DT 1_CD gene_NN ,_, one_CD in_IN exon_NN 17_CD and_CC another_DT one_CD in_IN exon_NN 23_CD ._.
        Sequence_NNP analysis_NN revealed_VBD a_DT T_NN to_TO C_NNP substitution_NN in_IN the_DT
        third_JJ position_NN of_IN codon_NN encoding_VBG alanine_NN at_IN 1403_CD position_NN
        (_( exon_NN 17_CD )_) of_IN mRNA_NN ._. Of_IN these_DT ,_, 6_CD individuals_NNS were_VBD homozygous_JJ
        CC_NNP (_( 29_CD %_NN )_) and_CC 15_CD were_VBD heterozygous_JJ TC_NNP (_( 71_CD %_NN )_) (_( exon_NN 17_CD )_) ._.
        However_RB ,_, there_EX was_VBD no_DT amino_JJ acid_NN change_NN ._. Substitution_NNP of_IN T_NN
        to_TO C_NNP in_IN normal_JJ members_NNS as_IN well_RB ,_, suggests_VBZ it_PRP is_VBZ a_DT
        polymorphic_JJ variant_NN and_CC not_RB a_DT pathogenic_JJ mutation_NN ._. In_IN exon_NN
        23_CD ,_, the_DT variation_NN observed_VBD was_VBD an_DT A_DT to_TO G_NNP substitution_NN in_IN
        the_DT untranslated_JJ region_NN at_IN position_NN 2242_CD of_IN mRNA_NN ._. Of_IN these_DT ,_,
        eighteen_NN were_VBD homozygous_JJ AA_NN (_( 86_CD %_NN )_) and_CC three_CD were_VBD
        heterozygous_JJ AG_NNP (_( 14_CD %_NN )_) ._. The_DT variant_NN in_IN exon_NN 17_CD was_VBD also_RB
        found_VBN in_IN the_DT SNP_NNP database_NN (_( NCBI_NNP SNP_NNP cluster_NN ID_NNP rs_NNS 1339067_CD )_)
        although_IN the_DT population_NN frequency_NN was_VBD not_RB reported_VBN ._. An_DT
        association_NN study_NN of_IN this_DT variant_NN in_IN a_DT large_JJ population_NN
        will_MD aid_VB in_IN understanding_VBG the_DT potential_JJ role_NN of_IN the_DT SLC_NNP 15_CD A_DT 1_CD
        gene_NN in_IN Bipolar_NNP disorder_NN ._.
        Alignment_NNP of_IN the_DT GPC_NNP 5_CD cDNA_NN with_IN the_DT working_VBG draft_NN
        sequence_NN revealed_VBD a_DT genomic_JJ organization_NN of_IN 8_CD exons_NNS ,_, which_WDT
        was_VBD represented_VBN in_IN 6_CD BAC_NNP clone_NN sequences_NNS (_( Table_NNP 2_LS )_) ._. The_DT
        whole_JJ GPC_NNP 5_CD gene_NN is_VBZ 2558_CD bp_NN long_JJ and_CC encodes_NNS 572_CD amino_JJ
        acids_NNS ._. The_DT first_JJ two_CD exons_NNS of_IN the_DT GPC_NNP 5_CD gene_NN are_VBP present_JJ in_IN
        BAC_NNP clone_NN accession_NN number_NN AL_NNP 138714_CD ,_, exons_NNS 3_CD ,_, 4_CD ,_, 5_CD in_IN
        AC_NNP 027429_CD ,_, exon_NN 6_CD in_IN AL_NNP 162456_CD ,_, exon_NN 7_CD in_IN AL_NNP 163537_CD and_CC exon_NN 8_CD
        in_IN AL_NNP 157363_CD (_( Table_NNP 2_LS )_) ._. Most_JJS of_IN the_DT splice_NN junctions_NNS follow_VBP
        the_DT GT_NNP /_NN AG_NNP rule_NN ._. The_DT exon_NN structure_NN was_VBD confirmed_VBN by_IN
        comparing_VBG the_DT cDNA_NN with_IN nucleotide_NN contig_NN NT_NNP __NN 009866_CD ._. While_IN
        we_PRP finished_VBD screening_VBG this_DT gene_NN for_IN mutations_NNS ,_, its_PRP$ genomic_JJ
        structure_NN was_VBD published_VBN and_CC confirms_VBZ the_DT presence_NN of_IN 8_CD
        exons_NNS with_IN exon_NN /_NN intron_NN boundaries_NNS following_VBG the_DT AG_NNP /_NN GT_NNP rule_NN
        with_IN a_DT size_NN of_IN approximately_RB 2_CD Mb_NNP [_NN 30_CD ]_NN ._. No_DT mutations_NNS or_CC
        polymorphisms_NNS were_VBD identified_VBN in_IN the_DT GPC_NNP 5_CD gene_NN in_IN the_DT 7_CD
        families_NNS affected_VBN with_IN Bipolar_NNP disorder_NN decreasing_VBG the_DT
        likelihood_NN that_IN this_DT gene_NN is_VBZ involved_VBN in_IN the_DT etiology_NN of_IN
        Bipolar_NNP disorder_NN ._. Several_JJ disorders_NNS have_VBP been_VBN reported_VBN due_JJ
        to_TO mutations_NNS in_IN glypican_NN gene_NN families_NNS [_NN 31_CD 37_CD ]_NN and_CC
        interestingly_RB due_JJ to_TO deletion_NN of_IN region_NN on_IN chr_NN ._. 13_CD q_NN 32_CD [_NN 24_CD
        38_CD ]_NN ._. It_PRP would_MD be_VB interesting_JJ to_TO study_VB the_DT occurrence_NN of_IN
        Schizophrenia_NNP or_CC other_JJ associated_VBN mental_JJ illnesses_NNS in_IN
        individuals_NNS with_IN these_DT deletions_NNS ._. Mutation_NNP screening_NN of_IN the_DT
        glypican_NN genes_NNS in_IN these_DT patients_NNS might_MD give_VB clue_NN to_TO
        Schizophrenia_NNP susceptibility_NN locus_JJ ._.
        Absence_NNP of_IN pathogenic_JJ mutations_NNS in_IN the_DT two_CD genes_NNS GPC_NNP 5_CD
        and_CC SLC_NNP 15_CD A_DT 1_CD studied_VBN in_IN seven_CD families_NNS of_IN Bipolar_NNP disorder_NN
        suggests_VBZ that_IN these_DT genes_NNS are_VBP presumably_RB not_RB involved_VBN in_IN
        the_DT susceptibility_NN locus_JJ for_IN Bipolar_NNP disorder_NN in_IN the_DT
        families_NNS screened_VBD ._. However_RB ,_, due_JJ to_TO the_DT complex_JJ nature_NN of_IN
        these_DT diseases_NNS ,_, no_DT definite_JJ conclusions_NNS can_MD be_VB drawn_VBN ._. We_PRP
        cannot_NN rule_NN out_IN genetic_JJ heterogeneity_NN for_IN these_DT genes_NNS and_CC
        suggest_VBP studying_VBG more_JJR families_NNS ._. For_IN example_NN ,_, the_DT NOTCH_NNP 4_CD
        gene_NN that_WDT is_VBZ located_VBN on_IN chromosome_NN 6_CD p_NN 21_CD ._. 3_LS confers_VBZ
        susceptibility_NN to_TO Schizophrenia_NNP in_IN the_DT British_JJ population_NN
        but_CC not_RB in_IN the_DT Japanese_JJ population_NN [_NN 39_CD ]_NN ._. Genetic_NNP
        heterogeneity_NN is_VBZ very_RB common_JJ in_IN hereditary_JJ deafness_NNS [_NN 40_CD ]_NN
        ;_: also_RB the_DT prevalence_NN of_IN mutations_NNS in_IN the_DT connexin_NN 26_CD gene_NN
        is_VBZ a_DT major_JJ cause_NN of_IN non-syndromic_JJ autosomal_NN recessive_JJ
        deafness_NNS that_WDT varies_VBZ in_IN different_JJ populations_NNS [_NN 41_CD ]_NN ._.
        Considering_VBG the_DT complex_JJ nature_NN of_IN the_DT disease_NN and_CC the_DT
        supportive_JJ evidence_NN of_IN linkage_NN to_TO chromosome_NN 13_CD q_NN 32_CD [_NN 13_CD 15_CD
        ]_NN it_PRP would_MD be_VB worth_JJ while_IN to_TO continue_VB further_JJ studies_NNS to_TO
        find_VB out_RP Schizophrenia_NNP susceptibility_NN genes_NNS at_IN this_DT
        critical_JJ region_NN ._. As_IN the_DT human_JJ genome_NN reference_NN sequence_NN is_VBZ
        nearing_VBG completion_NN ,_, the_DT analysis_NN of_IN genetic_JJ variation_NN is_VBZ
        becoming_VBG important_JJ ._. Our_PRP$ plans_NNS are_VBP to_TO annotate_NN all_DT the_DT genes_NNS
        for_IN a_DT 10_CD -_: mega_JJ base_NN region_NN on_IN chromosome_NN 13_CD and_CC develop_VB a_DT
        high_JJ density_NN SNP_NNP map_NN ._. Aim_NNP is_VBZ to_TO identify_VB variants_NNS in_IN the_DT
        critical_JJ region_NN ,_, to_TO predict_VB haplotypes_NNS from_IN numerous_JJ
        variants_NNS observed_VBD and_CC perform_VB mutation_NN analysis_NN by_IN direct_JJ
        sequencing_VBG with_IN the_DT ultimate_JJ objective_NN of_IN identifying_VBG
        specific_JJ sequence_NN /_NN haplotype_NN associated_VBN with_IN the_DT disease_NN
        phenotype_NN ._.
      
      
        Methods_NNP
        
          Study_NNP Subjects_NNP
          A_DT total_NN of_IN 7_CD nuclear_JJ families_NNS (_( n-_NN 20_CD )_) affected_VBN with_IN
          Bipolar_NNP disorder_NN were_VBD selected_VBN ._. The_DT seven_CD families_NNS
          consist_VBP of_IN five_CD normal_JJ parents_NNS ,_, five_CD affected_VBN parents_NNS ,_,
          seven_CD affected_VBN patients_NNS ,_, one_CD normal_JJ sib_NN and_CC two_CD affected_VBN
          members_NNS ._. These_DT families_NNS were_VBD selected_VBN from_IN four_CD known_VBN
          pedigree_NN series_NN with_IN evidence_NN of_IN linkage_NN to_TO chromosome_NN
          13_CD q_NN 32_CD [_NN 15_CD ]_NN ._.
        
        
          Genomic_NNP structure_NN determination_NN
          The_DT genomic_JJ structures_NNS of_IN SLC_NNP 15_CD A_DT 1_CD (_( accession_NN number_NN
          U_NNP 21936_CD )_) and_CC GPC_NNP 5_CD (_( accession_NN number_NN U_NNP 66033_CD )_) were_VBD
          determined_VBN by_IN direct_JJ comparison_NN of_IN their_PRP$ full-length_JJ cDNA_NN
          with_IN the_DT sequence_NN of_IN human_JJ chromosome_NN 13_CD genomic_JJ clones_NNS
          retrieved_VBD from_IN the_DT GenBank_NNP htgs_NNS database_NN
          http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN by_IN BLASTN_NNP searching_VBG ._. Intronic_NNP
          oligonucleotide_NN primer_NN pairs_NNS flanking_VBG the_DT coding_VBG
          fragments_NNS were_VBD designed_VBN for_IN both_DT the_DT genes_NNS using_VBG program_NN
          primer_NN 3_CD
          http_NN :_: /_NN /_NN www_NN ._. genome_NN ._. wi_NN ._. mit_NN ._. edu_NN /_NN cgi-bin_JJ /_NN primer_NN /_NN primer_NN 3_CD ._. cgiusing_VBG
          the_DT genomic_JJ sequences_NNS of_IN SLC_NNP 15_CD A_DT 1_CD and_CC GPC_NNP 5_CD gene_NN
          respectively_RB ._.
        
        
          Mutation_NNP analysis_NN
          Mutation_NNP screening_NN of_IN the_DT coding_VBG region_NN of_IN the_DT genes_NNS
          for_IN sequence_NN variants_NNS was_VBD performed_VBN by_IN PCR_NNP amplification_NN
          of_IN 20_CD samples_NNS of_IN 7_CD BP_NNP families_NNS and_CC a_DT control_NN sample_NN ._. Each_DT
          sample_NN was_VBD analyzed_VBN for_IN exon_NN 2_CD -_: 23_CD of_IN the_DT SLC_NNP 15_CD A_DT 1_CD gene_NN
          (_( Table_NNP 3_LS )_) and_CC 7_CD coding_VBG fragments_NNS of_IN the_DT GPC_NNP 5_CD gene_NN (_( Table_NNP
          4_LS )_) ._. Twenty_CD two_CD fragments_NNS of_IN the_DT SLC_NNP 15_CD A_DT 1_CD gene_NN were_VBD
          amplified_VBN in_IN eighteen_NN reactions_NNS P_NN 1_CD -_: P_NN 18_CD (_( Table_NNP 3_LS )_) ._. PCR_NNP
          reactions_NNS were_VBD carried_VBN out_IN under_IN the_DT standard_JJ PCR_NNP
          conditions_NNS ._. In_IN brief_VB each_DT 50_CD -_: ul_NN reaction_NN contained_VBD 50_CD ng_NN
          of_IN genomic_JJ DNA_NNP ,_, 20_CD pmole_NN of_IN each_DT primer_NN ,_, 1_CD unit_NN of_IN
          AmpliTaq_NNP Gold_NNP DNA_NNP polymerase_NN ,_, 5_CD ul_NN of_IN 10_CD X_NNP buffer_NN ,_, 2_CD ._. 5_CD ul_NN
          of_IN 2_CD ._. 5_CD mM_NN of_IN MgCl_NNP 
          2_CD &_CC 2_CD ._. 5_CD mM_NN of_IN dNTPs_NNS ._. Amplification_NNP
          conditions_NNS were_VBD 94_CD °_NN C_NNP /_NN 12_CD min_NN ,_, 45_CD cycles_NNS of_IN 94_CD °_NN C_NNP /_NN 30_CD s_VBZ ,_,
          60_CD °_NN C_NNP /_NN 30_CD s_VBZ ,_, 70_CD °_NN C_NNP /_NN 90_CD s_VBZ followed_VBN by_IN final_JJ extension_NN step_NN
          of_IN 70_CD °_NN C_NNP /_NN 5_CD min_NN ._. Sequences_NNP of_IN the_DT primers_NNS and_CC annealing_VBG
          temperature_NN of_IN each_DT amplification_NN are_VBP given_VBN in_IN Tables_NNP
          3_CD &_CC 4_CD ._. PCR_NNP products_NNS were_VBD analyzed_VBN using_VBG 2_CD %_NN agarose_NN gel_NN
          electrophoresis_NNS and_CC purified_JJ by_IN 96_CD well_RB Qia_NNP Quick_NNP PCR_NNP
          purification_NN kit_NN (_( Qiagen_NNP )_) ._. Sequencing_NNP of_IN each_DT exon_NN except_IN
          exon_NN 3_CD of_IN GPC_NNP 5_CD was_VBD performed_VBN using_VBG BODIPY_NNP dye_NN primer_NN
          chemistry_NN [_NN 42_CD ]_NN on_IN an_DT ABI_NNP 3700_CD DNA_NNP sequencer_NN (_( Applied_NNP
          Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Exon_NNP 3_CD of_IN GPC_NNP 5_CD was_VBD
          sequenced_JJ with_IN ABI_NNP Big_NNP Dye_NNP terminator_NN chemistry_NN ._. The_DT
          obtained_VBN sequences_NNS were_VBD compared_VBN with_IN the_DT corresponding_JJ
          control_NN gene_NN sequences_NNS using_VBG SEQUENCHER_NNP software_NN (_( Gene_NNP
          codes_NNS corporation_NN ,_, Ann_NNP Arbor_NNP ,_, MI_NNP ,_, USA_NNP )_) ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        Human_JJ peptide_NN transporter_NN :_: SLC_NNP 15_CD A_DT 1_CD
        Human_NNP Glypican_NNP 5_CD :_: GPC_NNP 5_CD
      
      
        Authors_NNP '_'' contributions_NNS
        MM_NNP carried_VBD out_IN mutation_NN screening_NN of_IN the_DT candidate_NN genes_NNS
        and_CC drafted_VBD the_DT manuscript_NN ._. SLC_NNP participated_VBD in_IN the_DT
        development_NN of_IN ~_NN 15_CD Mb_NNP map_NN region_NN on_IN human_JJ chromosome_NN 13_CD q_NN 32_CD ._.
        CYL_NNP &_CC Author_NN 4_CD ,_, SD_NNP Participated_NNP in_IN initial_JJ genotyping_VBG
        of_IN the_DT families_NNS ._. JAB_NNP did_VBD the_DT statistical_JJ analysis_NN to_TO select_VB
        the_DT pedigrees_NNS ._. ESG_NNP and_CC RAG_NNP are_VBP PI_NNP and_CC CO_NNP PI_NNP of_IN the_DT project_NN
        and_CC participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._.
      
      
        Addendum_NNP
        While_IN screening_VBG an_DT additional_JJ three_CD families_NNS ,_, and_CC
        reanalysis_NNS of_IN our_PRP$ previous_JJ families_NNS we_PRP noted_VBD two_CD variants_NNS
        in_IN exon_NN three_CD :_: One_CD was_VBD A_DT 155_CD V_NNP (_( C_NNP >_NN T_NN )_) and_CC second_RB was_VBD R_NN 223_CD C_NNP
        (_( C_NNP >_NN T_NN )_) ._. Of_IN the_DT 23_CD subjects_NNS studied_VBN ,_, 5_CD (_( 3_CD affected_VBN and_CC 2_CD
        normal_JJ )_) were_VBD heterozygous_JJ Ala_NNP /_NN Val_NNP ._. 1_LS (_( affected_VBN )_) homozygous_JJ
        Val_NNP /_NN Val_NNP and_CC 17_CD (_( 13_CD affected_VBN and_CC 4_CD normal_JJ )_) were_VBD homozygous_JJ
        Ala_NNP /_NN Ala_NNP ._. The_DT second_JJ variant_NN R_NN 223_CD C_NNP was_VBD observed_VBN in_IN 2_CD (_( 1_CD
        affected_VBN and_CC 1_CD normal_JJ )_) subjects_NNS ,_, both_DT were_VBD heterozygous_JJ
        Arg_NNP /_NN Cys_NNP ,_, 16_CD affected_VBN and_CC 5_CD normal_JJ subjects_NNS were_VBD homozygous_JJ
        Arg_NNP /_NN Arg_NNP and_CC none_NN were_VBD Cys_NNP /_NN Cys_NNP homozygous_JJ ._. An_DT association_NN
        study_NN of_IN the_DT variants_NNS detected_VBD in_IN GPC_NNP 5_CD and_CC SLC_NNP 15_CD A_DT 1_CD genes_NNS in_IN
        a_DT large_JJ gene_NN population_NN will_MD aid_VB in_IN understanding_VBG the_DT
        potential_JJ role_NN of_IN these_DT genes_NNS in_IN Bipolar_NNP disorders_NNS ._.
      
    
  
